An excellent summary about the potential of our lead program, OXU-001, from Drug Discovery World.
“An innovative sustained release formulation of dexamethasone currently under investigation for use in DME offers the potential for effective anti-inflammatory treatment with significantly fewer injections and a high likelihood of fewer side effects, as its levels in the vitreous and anterior segment are minimal. This will limit the frequency of IOP elevation and cataract and maintain visual benefits long-term. Once-yearly dosing would reduce the burden of treatment for patients with DME and make maintaining compliance much easier to achieve.”
